WO2003008637A3 - Use of genotyping in the individualization of therapy - Google Patents

Use of genotyping in the individualization of therapy Download PDF

Info

Publication number
WO2003008637A3
WO2003008637A3 PCT/CA2002/001103 CA0201103W WO03008637A3 WO 2003008637 A3 WO2003008637 A3 WO 2003008637A3 CA 0201103 W CA0201103 W CA 0201103W WO 03008637 A3 WO03008637 A3 WO 03008637A3
Authority
WO
WIPO (PCT)
Prior art keywords
individualization
therapy
genotyping
relates
specifically
Prior art date
Application number
PCT/CA2002/001103
Other languages
French (fr)
Other versions
WO2003008637A2 (en
Inventor
Brian Leyland-Jones
Original Assignee
Univ Mcgill
Brian Leyland-Jones
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcgill, Brian Leyland-Jones filed Critical Univ Mcgill
Publication of WO2003008637A2 publication Critical patent/WO2003008637A2/en
Publication of WO2003008637A3 publication Critical patent/WO2003008637A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The invention relates to the individualization of therapy. More specifically, the present invention relates to the use of genotyping for the individualization of therapy and/or individualization of drug dosing. More specifically, the present invention relates to the use of genotyping in the individualization of therapy with a therapeutic agent or a class of therapeutic agents.
PCT/CA2002/001103 2001-07-17 2002-07-17 Use of genotyping in the individualization of therapy WO2003008637A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30563001P 2001-07-17 2001-07-17
US60/305,630 2001-07-17

Publications (2)

Publication Number Publication Date
WO2003008637A2 WO2003008637A2 (en) 2003-01-30
WO2003008637A3 true WO2003008637A3 (en) 2003-10-16

Family

ID=23181620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/001103 WO2003008637A2 (en) 2001-07-17 2002-07-17 Use of genotyping in the individualization of therapy

Country Status (1)

Country Link
WO (1) WO2003008637A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5348840B2 (en) 2003-02-20 2013-11-20 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ How to choose a drug
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
WO2005038049A2 (en) * 2003-10-06 2005-04-28 Heinrich Guenther System and method for optimizing drug therapy
US8518022B2 (en) 2004-08-27 2013-08-27 Medimetrics Personalized Drug Delivery, Inc. Electronically and remotely controlled pill and system for delivering at least one medicament
JP2009517186A (en) * 2005-11-29 2009-04-30 チルドレンズ ホスピタル メディカル センター Drug selection and medication optimization and personalization
US8099298B2 (en) 2007-02-14 2012-01-17 Genelex, Inc Genetic data analysis and database tools
CN101983029B (en) 2008-03-31 2015-01-14 皇家飞利浦电子股份有限公司 Method of preparing a swallowable capsule comprising a sensor
WO2009153739A1 (en) 2008-06-19 2009-12-23 Koninklijke Philips Electronics N.V. Device for delivery of powder like medication in a humid environment
WO2009156919A1 (en) 2008-06-25 2009-12-30 Koninklijke Philips Electronics N.V. Electronic pill comprising a plurality of medicine reservoirs
EP2464414B1 (en) 2009-08-12 2013-06-12 Medimetrics Personalized Drug Delivery B.V. Drug delivery device with compressible drug reservoir
WO2014121133A2 (en) 2013-02-03 2014-08-07 Genelex Corporation Systems and methods for quantification and presentation of medical risk arising from unknown factors
US20140274763A1 (en) * 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to pain treatments

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055624A2 (en) * 1999-03-15 2000-09-21 Leyland Jones Brian Elisa kit for the determination of metabolic phenotypes
WO2002088753A1 (en) * 2001-04-26 2002-11-07 Mcgill University Individualization of therapy with erectile dysfunction agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055624A2 (en) * 1999-03-15 2000-09-21 Leyland Jones Brian Elisa kit for the determination of metabolic phenotypes
WO2002088753A1 (en) * 2001-04-26 2002-11-07 Mcgill University Individualization of therapy with erectile dysfunction agents

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BROCKMÖLLER J ET AL: "Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment.", PHARMACOGENOMICS. ENGLAND MAY 2000, vol. 1, no. 2, May 2000 (2000-05-01), pages 125 - 151, XP008020668, ISSN: 1462-2416 *
ERESHEFSKY L ET AL: "REVIEW OF THE PHARMACOKINETICS, PHARMACOGENETICS, AND DRUG INTERACTION POTENTIAL OF ANTIDEPRESSANTS: FOCUS ON VENLAFAXINE", DEPRESSION AND ANXIETY, NEW YORK, NY, US, vol. 12, no. SUPPL 1, 2000, pages 30 - 44, XP009000372, ISSN: 1091-4269 *
GRIESE E-U ET AL: "ASSESSMENT OF THE PREDICTIVE POWER OF GENOTYPES FOR THE IN-VIVO CATALYTIC FUNCTION OF CYP2D6 IN A GERMAN POPULATION", PHARMACOGENETICS, CHAPMAN & HALL, LONDON, GB, vol. 8, no. 1, February 1998 (1998-02-01), pages 15 - 26, XP001073429, ISSN: 0960-314X *
INGELMAN-SUNDBERG M ET AL: "Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 20, no. 8, 1 August 1999 (1999-08-01), pages 342 - 349, XP004173660, ISSN: 0165-6147 *
LU A Y H: "Drug-metabolism research challenges in the new millennium: Individual variability in drug therapy and drug safety", DRUG METABOLISM AND DISPOSITION, WILLIAMS AND WILKINS., BALTIMORE, MD, US, vol. 26, no. 12, December 1998 (1998-12-01), pages 1217 - 1222, XP002223866, ISSN: 0090-9556 *
MANCINELLI L ET AL: "Pharmacogenomics: the promise of personalized medicine.", AAPS PHARMSCI [ELECTRONIC RESOURCE]. UNITED STATES 2000, vol. 2, no. 1, March 2000 (2000-03-01), pages E4, XP002251962, ISSN: 1522-1059 *
MARCH R: "PHARMACOGENOMICS: THE GENOMICS OF DRUG RESPONSE", YEAST, CHICHESTER, SUSSEX, GB, vol. 17, no. 1, 2000, pages 16 - 21, XP001064496, ISSN: 0749-503X *
MCELROY S ET AL: "CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting.", AAPS PHARMSCI [ELECTRONIC RESOURCE]. UNITED STATES 2000, vol. 2, no. 4, 2000, pages E33, XP002251960, ISSN: 1522-1059 *
MEISEL C ET AL: "HOW TO MANAGE INDIVIDUALIZED DRUG THERAPY: APPLICATION OF PHARMACOGENETIC KNOWLEDGE OF DRUG METABOLISM AND TRANSPORT", CLINICAL CHEMISTRY AND LABORATORY MEDICINE, WALTER DE GRUYTER UND CO, DE, vol. 38, no. 9, September 2000 (2000-09-01), pages 869 - 876, XP001030015, ISSN: 1434-6621 *
STREETMAN D S ET AL: "Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.", PHARMACOGENETICS. ENGLAND APR 2000, vol. 10, no. 3, April 2000 (2000-04-01), pages 187 - 216, XP008020500, ISSN: 0960-314X *

Also Published As

Publication number Publication date
WO2003008637A2 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
WO2004006858A3 (en) Compounds, compositions, and methods employing same
HK1061679A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-ibe derivatives, their preparation and their therapeutic use.
WO2004021968A3 (en) Solution for ungual application
DE60115029D1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING CANNABIDIOL DERIVATIVES
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
IL157656A (en) Metalloproteinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases mediated by metalloproteinase enzymes
IL151400A0 (en) Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
WO2002069945A3 (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
WO2005038049A3 (en) System and method for optimizing drug therapy
ID30116A (en) PIRIDOPIRANOAZEPIN DECREASES, THE PRODUCTION AND USE OF THERAPY
WO2003008637A3 (en) Use of genotyping in the individualization of therapy
HK1068606A1 (en) Novel aminobenzoephenones
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
ID26612A (en) SICLOBUTENA DECLARATIONS, THEIR PRODUCTION AND THE USE OF THERAPY
EP1257255A4 (en) Therapeutic product, use and formulation thereof
EE200300363A (en) Use of N- (Pyridinyl) -1H-Indole-1-Amine Compounds in the manufacture of a medicament for the treatment of diseases and conditions associated with myelin loss
WO2002053090A3 (en) Medicinal association of a biguanine (metformin) and arginine
ZA200400313B (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine.
AU2001243515A1 (en) Combination drug therapy
TWI320413B (en) 1,4-diazabicyclo [ 3.2.2 ] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof
WO2002053149A3 (en) Medicament containing a polyamine as an active substance
HUP0204208A2 (en) Antipruritic agents for external use
NO20042846L (en) Derivatives of 5- (pyridin-3-yl) -1-azabicyclo [3.2.1] octane, preparation thereof and use of the same as therapeutic agents
AU2002244575A1 (en) Individualization of therapy with antidepressants
AU2002349225A1 (en) Individualization of therapy with antiviral agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWW Wipo information: withdrawn in national office

Ref document number: 2002354840

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642